• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P-糖蛋白抗体功能化碳纳米管克服人白血病细胞的多药耐药性。

P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells.

机构信息

National Chromatographic R&A Center, CAS Key Laboratory of Separation Sciences for Analytical Chemistry,Dalian Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Dalian 116023, China.

出版信息

ACS Nano. 2010 Mar 23;4(3):1399-408. doi: 10.1021/nn9011225.

DOI:10.1021/nn9011225
PMID:20148593
Abstract

Multidrug resistance (MDR), which is related to cancer chemotherapy, tumor stem cells, and tumor metastasis, is a huge obstacle for the effective cancer therapy. One of the underlying mechanisms of MDR is the increased efflux of anticancer drugs by overexpressed P-glycoprotein (P-gp) of multidrug resistant cells. In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. The resulting Ap-SWNTs could not only specifically recognize the multidrug resistant human leukemia cells (K562R), but also demonstrate the effective loading and controllable release performance for Dox toward the target K562R cells by exposing to near-infrared radiation (NIR). The recognition capability of Ap-SWNTs toward the K562R cells was confirmed by flow cytometry (FCM) and confocal laser scanning microscopy (CLSM). The binding affinity of Ap-SWNTs toward drug-resistant K562R cells was ca. 23-fold higher than that toward drug-sensitive K562S cells. Additionally, CLSM indicated that Ap-SWNTs could specifically localize on the cell membrane of K562R cells and the fluorescence of Dox in K562R cells could be significantly enhanced after the employment of Ap-SWNTs as carrier. Moreover, the composite of Dox and Ap-SWNTs (Dox/Ap-SWNTs) expressed 2.4-fold higher cytotoxicity and showed the significant cell proliferation suppression toward K562R leukemia cells (p < 0.05) as compared with free Dox which is popularly employed in clinic trials. These results suggest that the Ap-SWNTs are the promising drug delivery vehicle for overcoming the MDR induced by the overexpression of P-gp on cell membrane. Ap-SWNTs loaded with drug molecules could be used to suppress the proliferation of multidrug resistant cells, destroy the tumor stem cells, and inhibit the metastasis of tumor.

摘要

多药耐药性(MDR)与癌症化疗、肿瘤干细胞和肿瘤转移有关,是癌症有效治疗的巨大障碍。MDR 的一个潜在机制是多药耐药细胞中过表达的 P 糖蛋白(P-gp)增加了抗癌药物的外排。在这项工作中,合成了载有阿霉素(Dox)的 P-gp(抗-P-gp)功能化的水溶性单壁碳纳米管(Ap-SWNTs)负载药物(Dox/Ap-SWNTs),用于挑战人白血病 K562 细胞的多药耐药性。结果表明,Ap-SWNTs 不仅可以特异性识别多药耐药的人白血病细胞(K562R),而且通过暴露于近红外辐射(NIR),对靶标 K562R 细胞表现出有效的载药和可控释放性能。通过流式细胞术(FCM)和共聚焦激光扫描显微镜(CLSM)证实了 Ap-SWNTs 对 K562R 细胞的识别能力。Ap-SWNTs 对耐药 K562R 细胞的结合亲和力约为对敏感 K562S 细胞的 23 倍。此外,CLSM 表明 Ap-SWNTs 可以特异性定位于 K562R 细胞的细胞膜上,并且在将 Ap-SWNTs 用作载体后,K562R 细胞中的 Dox 荧光可以显著增强。此外,与广泛用于临床试验的游离 Dox 相比,Dox/Ap-SWNTs (Dox/Ap-SWNTs)的组合表现出 2.4 倍更高的细胞毒性,并对 K562R 白血病细胞表现出显著的细胞增殖抑制作用(p <0.05)。这些结果表明,Ap-SWNTs 是克服细胞膜上过表达 P-gp 引起的多药耐药性的有前途的药物传递载体。负载药物分子的 Ap-SWNTs 可用于抑制多药耐药细胞的增殖,破坏肿瘤干细胞并抑制肿瘤转移。

相似文献

1
P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells.P-糖蛋白抗体功能化碳纳米管克服人白血病细胞的多药耐药性。
ACS Nano. 2010 Mar 23;4(3):1399-408. doi: 10.1021/nn9011225.
2
Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.通过杂交细胞穿透肽和药物结合肽降低 P-糖蛋白过表达细胞中的多柔比星耐药性。
J Drug Target. 2010 Jul;18(6):477-87. doi: 10.3109/10611860903548347.
3
Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.古古甾酮对阿霉素耐药的人髓性白血病(K562/DOX)细胞中P-糖蛋白介导的多药耐药的逆转作用
Pharmazie. 2009 Oct;64(10):660-5.
4
Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.从十大功劳茎中提取的异喹啉生物碱异粉防己碱对人乳腺癌(MCF-7/DOX)细胞中P-糖蛋白介导的阿霉素耐药性的逆转作用。
Yao Xue Xue Bao. 2008 May;43(5):461-6.
5
Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.新型CA-4类似物MZ3对白血病细胞的抗多药耐药作用及机制
Pharmazie. 2008 Jul;63(7):528-33.
6
Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.采用激光共聚焦显微荧光光谱法研究S9788、环孢素A和维拉帕米对多药耐药K562肿瘤细胞中THP-阿霉素细胞内分布的影响。
Anticancer Res. 1994 Nov-Dec;14(6A):2389-93.
7
Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.抗癌药物诱导MOLT-4细胞产生多药耐药性与功能性P-糖蛋白和MDR1 mRNA表达增加密切相关。
Cancer Chemother Pharmacol. 2002 May;49(5):391-7. doi: 10.1007/s00280-001-0411-5. Epub 2002 Feb 14.
8
CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.异黄酮CJY可逆转P-糖蛋白介导的多药耐药性,该耐药性存在于对阿霉素耐药的人髓性白血病(K562/DOX)细胞中。
J Pharm Pharmacol. 2007 Jul;59(7):1011-5. doi: 10.1211/jpp.59.7.0014.
9
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.汉防己甲素对多药耐药人T淋巴母细胞白血病MOLT-4细胞中P-糖蛋白介导的柔红霉素耐药性的持续逆转作用
J Pharm Pharmacol. 2003 Nov;55(11):1531-7. doi: 10.1211/0022357022115.
10
Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.多柔比星耐药K562细胞中P-糖蛋白的线粒体定位及活性
Biochem Pharmacol. 2006 Apr 14;71(8):1162-74. doi: 10.1016/j.bcp.2006.01.006. Epub 2006 Feb 24.

引用本文的文献

1
Application of artificial intelligence-based stemness index in cancer.基于人工智能的干性指数在癌症中的应用。
Front Oncol. 2025 Aug 13;15:1608712. doi: 10.3389/fonc.2025.1608712. eCollection 2025.
2
Carbon Nanotubes as Excellent Adjuvants for Anticancer Therapeutics and Cancer Diagnosis: A Plethora of Laboratory Studies Versus Few Clinical Trials.碳纳米管作为抗癌治疗和癌症诊断的优异佐剂:大量实验室研究与少量临床试验
Cells. 2025 Jul 9;14(14):1052. doi: 10.3390/cells14141052.
3
Exploration of the photothermal role of curcumin-loaded targeted carbon nanotubes as a potential therapy for melanoma cancer.
载姜黄素靶向碳纳米管的光热作用探索——一种治疗黑色素瘤癌症的潜在疗法。
Sci Rep. 2024 May 2;14(1):10117. doi: 10.1038/s41598-024-57612-y.
4
The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment.血液系统恶性肿瘤治疗中的临床方案及细胞膜伪装纳米药物递送系统
Front Pharmacol. 2024 Apr 16;15:1376955. doi: 10.3389/fphar.2024.1376955. eCollection 2024.
5
A Review on Carbon Nanotubes Family of Nanomaterials and Their Health Field.碳纳米管纳米材料家族及其健康领域综述
ACS Omega. 2024 Feb 13;9(8):8687-8708. doi: 10.1021/acsomega.3c08824. eCollection 2024 Feb 27.
6
Anticancer Activity of Au/CNT Nanocomposite Fabricated by Nanosecond Pulsed Laser Ablation Method on Colon and Cervical Cancer.纳秒脉冲激光烧蚀法制备的金/碳纳米管纳米复合材料对结肠癌和宫颈癌的抗癌活性
Micromachines (Basel). 2023 Jul 20;14(7):1455. doi: 10.3390/mi14071455.
7
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.纳米材料、纳米技术和纳米医学在治疗血液系统恶性肿瘤中的发展与应用。
J Hematol Oncol. 2023 Jun 23;16(1):65. doi: 10.1186/s13045-023-01460-2.
8
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.新兴纳米技术治疗药物对抗多药耐药性癌症。
J Nanobiotechnology. 2022 Sep 24;20(1):423. doi: 10.1186/s12951-022-01626-z.
9
Nanomedicine and versatile therapies for cancer treatment.用于癌症治疗的纳米医学与通用疗法。
MedComm (2020). 2022 Aug 18;3(3):e163. doi: 10.1002/mco2.163. eCollection 2022 Sep.
10
Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance.探索近红外吸收纳米载体以克服癌症耐药性。
Cancer Drug Resist. 2020 Jul 2;3(3):302-333. doi: 10.20517/cdr.2020.20. eCollection 2020.